Summary: Researchers have identified a naturally occurring lipid molecule, erucamide, as a key coordinator of the retina’s protective response to injury. The team found that endogenous erucamide levels fall sharply as light-sensing photoreceptors degenerate, and that restoring erucamide stabilizes the retinal neurovascular unit. Rather than acting directly on photoreceptors, erucamide binds to the TMEM19 protein on CD11b⁺ myeloid immune cells, triggering localized signals that preserve blood vessels and surrounding neural tissue.
Delivered using engineered porous silicon nanoparticles to overcome its natural hydrophobicity, erucamide slowed retinal tissue breakdown in preclinical models. These results reveal a promising therapeutic approach for progressive blinding diseases by enhancing the retina’s own protective signaling rather than attempting to rescue dying photoreceptors directly.
Key Facts
- Endogenous signaling decline: Erucamide is a naturally occurring fatty acid amide whose levels decline markedly as photoreceptor cells die during progressive retinal disease.
- Environment-targeting strategy: Rather than targeting photoreceptors directly, erucamide-based interventions act on the surrounding neurovascular environment to preserve structure and function.
- TMEM19 receptor mechanism: TMEM19 is a binding protein required for erucamide’s effects; reducing TMEM19 blocks myeloid cell activation and erucamide’s protective action.
- Nanoparticle delivery: Because erucamide is hydrophobic and prone to aggregating in aqueous solutions, porous silicon nanoparticles were used to ensure stable, uniform ocular delivery.
- Broad therapeutic potential: By stabilizing the neurovascular unit, this approach could have implications for diseases such as diabetic retinopathy, retinitis pigmentosa, and age-related macular degeneration.
Source: Scripps Research Institute
Overview
Many causes of vision loss share a central process: progressive breakdown of the retina, the light-sensitive tissue at the back of the eye. While structural changes during degeneration are well described, the molecular signals that shape the retina’s response to injury are less well understood. A collaborative team from Scripps Research, UC San Diego, and the Lowy Medical Research Institute investigated these molecular signals and identified erucamide as an important component of the retina’s adaptive response.
Published in Nature Neuroscience on June 19, 2026, the study shows that erucamide levels fall as photoreceptors begin to die, and that reintroducing erucamide triggers cellular responses that support retinal stability. These findings suggest that erucamide is part of a natural protective mechanism and that modulating this pathway can slow degeneration.
“The retina does not simply fall apart; it actively responds to injury,” says Martin Friedlander, senior author and professor at Scripps Research. “Our data identify erucamide as a signaling molecule that helps coordinate that response.”
The retina relies on tight communication between neurons, glia, blood vessels and immune cells—collectively known as the neurovascular unit—to maintain function. In conditions such as diabetic retinopathy, retinitis pigmentosa, and age-related macular degeneration, this coordination deteriorates: photoreceptors decline and vision fades. The current study builds on observations that transplanted stem cell–derived retinal cells could slow degeneration even after the transplanted cells disappeared, suggesting the release of durable protective signals. That observation motivated a search for the responsible molecules.
Using high-resolution, mass spectrometry–based metabolomics, the researchers screened multiple preclinical models of retinal degeneration to track small molecules that change during disease progression. Among many candidates, erucamide stood out: its concentration dropped sharply at the same time photoreceptors began to degenerate, suggesting it plays an active role in the disease timeline rather than being a mere byproduct.
To test whether restoring erucamide could influence degeneration, the team used organosilane-modified porous silicon nanoparticles as delivery vehicles. Erucamide is highly hydrophobic and aggregates in aqueous environments, making conventional ocular formulations ineffective. Encapsulation in porous silicon nanoparticles enabled stable, controlled release across retinal tissue and prevented clumping after injection.
In treated eyes, erucamide did not act directly on photoreceptors. Instead, it activated CD11b⁺ myeloid immune cells in the retina. The researchers identified TMEM19 as an erucamide-binding protein required for this activation: genetic or structural reduction of TMEM19 abolished myeloid cell activation and prevented the protective effects. Activated myeloid cells released angiogenic and neurotrophic signals that supported both blood vessels and neural elements, slowing structural and functional decline without fully reversing existing damage.
“Targeting the microenvironment rather than the dying photoreceptors reframes therapeutic strategy,” notes Guoqin Wei, first author and staff scientist at Scripps Research. “Supporting the neurovascular unit can give remaining visual cells the structural support they need to persist.”
The study clarifies an important molecular link but leaves open questions about the complete signaling cascade. Future research will evaluate erucamide signaling across different retinal diseases, test optimized formulations and modified analogs for improved efficacy and stability, and explore whether related lipids might offer stronger protective responses.
Overall, the findings highlight a strategy of harnessing or enhancing endogenous signaling molecules to strengthen tissue resilience under stress. Reinforcing a naturally present protective signal like erucamide could become a new avenue for slowing retinal degeneration in diseases that currently have limited treatment options.
Funding: This work received support from the Lowy Medical Research Institute; the National Eye Institute (grants R01EY11254 and 5R24EY017540); the California Institute for Regenerative Medicine (grant TR1-01219); the National Science Foundation via the UC San Diego Materials Research Science and Engineering Center (grant DMR-2011924); the National Institutes of Health (grants 2R01AI132413, R35 GM130385, U01 CA235493 and U01 CA305256); the National Institute on Drug Abuse (grant DA015648); the San Diego Nanotechnology Infrastructure of UC San Diego supported by the National Science Foundation (grant ECCS-2025752); and the Natural Sciences and Engineering Research Council of Canada Postgraduate Scholarship–Doctoral program (grant NSERC PGS-D).
Key Questions Answered
Q: How was erucamide isolated from thousands of organic molecules?
A: The team applied mass spectrometry–based metabolomics, which profiles hundreds of small lipids and metabolites simultaneously. Tracking multiple preclinical retinal degeneration models over time revealed erucamide’s concentration dropped in direct concert with photoreceptor loss, flagging it as a candidate mediator rather than a passive marker.
Q: Why are engineered nanoparticles needed for ocular delivery of erucamide?
A: Erucamide is highly hydrophobic and does not dissolve well in aqueous media. Direct injection causes the molecule to clump into unstable aggregates in the eye. Encapsulating erucamide in porous silicon nanoparticles prevents aggregation, enabling stable, uniform distribution and controlled release across damaged retinal layers.
Q: Why target CD11b⁺ myeloid cells instead of photoreceptors?
A: Directly preserving dying photoreceptors is challenging once supporting tissues deteriorate. Activating CD11b⁺ myeloid cells through TMEM19 stimulates these helper cells to secrete angiogenic and neurotrophic factors that stabilize the neurovascular unit. By restoring the environment first, the remaining photoreceptors receive the structural and vascular support they need to survive longer.
Editorial Notes:
- This article was edited for clarity and readability.
- The original journal paper was reviewed in full.
- Additional context was provided by the editorial staff.
About this visual neuroscience research news
Author: Press Office
Source: Scripps Research
Contact: Press Office – Scripps Research
Image: Image credit: Neuroscience News
Original Research: Open access. “A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration” by Guoqin Wei et al., Nature Neuroscience. DOI: 10.1038/s41593-026-02341-w
Abstract
A fatty acid amide activates myeloid cells and improves neurovascular outcomes in retinal degeneration
Breakdown of neurovasculoglial cross-talk underlies many central nervous system degenerative disorders, including retinal disease. Primary fatty acid amides can regulate interactions between vasculature and neuronal tissues, but the specific molecules and mechanisms have been unclear. Using an unbiased high-resolution metabolomics screen, the authors identified erucamide, a 22:1 monounsaturated omega-9 fatty acid amide, as highly dysregulated during photoreceptor degeneration in mice.
In vivo delivery of erucamide via organosilane-modified porous silicon nanoparticles activated retinal myeloid cells, inducing upregulation of angiogenic and neurotrophic cytokines that limited vascular and neuronal degeneration. The team identified TMEM19 as an erucamide-binding protein essential for myeloid activation and subsequent neuroprotection. These findings reveal a previously unrecognized fatty acid amide pathway that modulates neuroimmune interactions in retinal degeneration and propose erucamide and its analogs as candidate therapeutics.